Drugs / CX2101A enteric-coated
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06864182 | Mar → May 2024 | COVID-19 | Heronova Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX2101A enteric-coated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06864182 ↗ |